共 230 条
[1]
Xu Y(2016)Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis Int J Neuropsychopharmacol 19 pyv124-4
[2]
Hackett M(2019)Esketamine for treatment-resistant depression—first FDA-approved antidepressant in a new class N Engl J Med 381 1-56
[3]
Carter G(2016)Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression Acta Psychiatr Scand 134 48-272
[4]
Loo C(2020)Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: exploratory double-blind psychoactive-controlled replication study J Psychopharmacol 34 267-159
[5]
Gálvez V(2018)Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development Front Pharmacol 9 733-486
[6]
Glozier N(2014)(R, S)-Ketamine metabolites (R, S)-norketamine and (2S, 6S)-hydroxynorketamine increase the mammalian target of rapamycin function Anesthesiology 121 149-26
[7]
Glue P(2016)NMDAR inhibition-independent antidepressant actions of ketamine metabolites Nature 533 481-113
[8]
Lapidus K(2019)Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study Br J Psychiatry 214 20-269
[9]
McGirr A(2016)Oral ketamine for the treatment of pain and treatment-resistant depression Br J Psychiatry 208 108-136
[10]
Somogyi AA(2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 264-542